OLMA

SEC source: 0000935836-23-000733 · ownership.xml · nonDerivative · entry 2

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See note

Disclosed balance after: 1,700,000

F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-23-015701 · form4-12012023_051201.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 926,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $12.57, and the range of prices was between $12.30 and $13.02. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015455 · form4-11222023_071101.xml · nonDerivative · entry 4

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 424,987

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F6 · price: The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.17. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015457 · form4-11222023_071105.xml · nonDerivative · entry 3

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 951,283

F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F4 · price: The weighted average sale price for the transaction reported was $13.90, and the range of prices was between $13.62 and $14.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015459 · form4-11222023_071111.xml · nonDerivative · entry 4

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,664

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F6 · price: The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015458 · form4-11222023_071109.xml · nonDerivative · entry 4

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 574,099

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F6 · price: The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.15. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015456 · form4-11222023_071103.xml · nonDerivative · entry 4

Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,925

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F6 · price: The weighted average sale price for the transaction reported was $13.90, and the range of prices was between $13.62 and $14.16. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015455 · form4-11222023_071101.xml · nonDerivative · entry 3

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 434,132

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F5 · price: The weighted average sale price for the transaction reported was $15.27, and the range of prices was between $15.22 and $15.38. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015455 · form4-11222023_071101.xml · nonDerivative · entry 2

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 434,832

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F4 · price: The weighted average sale price for the transaction reported was $14.83, and the range of prices was between $14.18 and $15.17. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015457 · form4-11222023_071105.xml · nonDerivative · entry 2

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 955,272

F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F3 · price: The weighted average sale price for the transaction reported was $14.86, and the range of prices was between $14.26 and $15.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015459 · form4-11222023_071111.xml · nonDerivative · entry 3

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,759

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F5 · price: The weighted average sale price for the transaction reported was $15.33, and the range of prices was between $15.29 and $15.38. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015459 · form4-11222023_071111.xml · nonDerivative · entry 2

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,959

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F4 · price: The weighted average sale price for the transaction reported was $14.83, and the range of prices was between $14.25 and $15.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015458 · form4-11222023_071109.xml · nonDerivative · entry 3

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 580,752

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F5 · price: The weighted average sale price for the transaction reported was $15.32, and the range of prices was between $15.28 and $15.35. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015458 · form4-11222023_071109.xml · nonDerivative · entry 2

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 580,952

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F4 · price: The weighted average sale price for the transaction reported was $14.87, and the range of prices was between $14.26 and $15.25. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015456 · form4-11222023_071103.xml · nonDerivative · entry 3

Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,857

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F5 · price: The weighted average sale price for the transaction reported was $15.29, and the range of prices was between $15.20 and $15.95. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015456 · form4-11222023_071103.xml · nonDerivative · entry 2

Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,459

F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F4 · price: The weighted average sale price for the transaction reported was $14.84, and the range of prices was between $14.20 and $15.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-015455 · form4-11222023_071101.xml · nonDerivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 443,729

F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 105,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria.

F2 · balance_after: Includes 9,034 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2023 and 1,748 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2023.

SEC source: 0001415889-23-015457 · form4-11222023_071105.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 959,464

F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 45,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria.

SEC source: 0001415889-23-015459 · form4-11222023_071111.xml · nonDerivative · entry 1

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,220

F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 80,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria.

F2 · balance_after: Includes 3,609 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2022 and 13,611 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2023.

SEC source: 0001415889-23-015458 · form4-11222023_071109.xml · nonDerivative · entry 1

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 587,728

F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 75,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria.

F2 · balance_after: Includes 208 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2023.

SEC source: 0001415889-23-015456 · form4-11222023_071103.xml · nonDerivative · entry 1

Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,150

F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 315,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria.

F2 · balance_after: Includes 5,000 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2022 and 12,621 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2023.

SEC source: 0001415889-23-015041 · form4-11132023_051101.xml · nonDerivative · entry 1

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 561,270

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023.

F2 · price: The weighted average sale price for the transaction reported was $17.61, and the range of prices were between $17.52 and $17.69. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-014792 · form4-11042023_011159.xml · nonDerivative · entry 3

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 561,470

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023.

F4 · price: The weighted average sale price for the transaction reported was $17.51, and the range of prices were between $17.50 and $17.53. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-014714 · form4-11032023_121146.xml · nonDerivative · entry 2

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 943,714

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F3 · price: The weighted average sale price for the transaction reported was $15.64, and the range of prices were between $15.55 and $15.75. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-014792 · form4-11042023_011159.xml · nonDerivative · entry 2

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 562,011

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023.

F3 · price: The weighted average sale price for the transaction reported was $15.36, and the range of prices were between $15.01 and $15.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-014792 · form4-11042023_011159.xml · nonDerivative · entry 1

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 565,343

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023.

F2 · price: The weighted average sale price for the transaction reported was $15.02, and the range of prices were between $15.00 and $15.09. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-014714 · form4-11032023_121146.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 948,714

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $12.05, and the range of prices were between $11.19 and $13.24. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-014345 · form4-10172023_081046.xml · derivative · entry 2

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,347

Underlying: Common Stock · 14,347 shares

Expires 2033-10-15

F2 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments measured from October 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares will vest in full on the earlier of June 16, 2024 and the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-23-014345 · form4-10172023_081046.xml · derivative · entry 1

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2033-10-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthly installments measured from October 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-23-013898 · form4-10032023_051008.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 973,714

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $12.41, and the range of prices were between $11.86 and $13.18. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-013474 · form4-09212023_050902.xml · nonDerivative · entry 1

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 572,011

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated June 20, 2023.

F2 · price: The weighted average sale price for the transaction reported was $12.67, and the range of prices were between $12.31 and $12.85. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · balance_after: Includes 1,446 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2022, and 7,664 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2023.

SEC source: 0000921895-23-002167 · form407422olma_09142023.xml · nonDerivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · Director · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 99,556

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F7 · kind: Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account.

F7 · price: Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account.

F7 · ownership.direct: Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account.

F7 · ownership.nature: Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account.

SEC source: 0000921895-23-002167 · form407422olma_09142023.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · Director · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 524,151

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · shares: The Issuer entered into a securities purchase agreement with certain purchasers, including certain of the Reporting Persons (the "Purchasers"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the "Private Placement") shares of the Issuer's Common Stock at a per share purchase price equal to $9.84.

F3 · shares: Shares of the Issuer's Common Stock purchased in the Private Placement.

F2 · price: The Issuer entered into a securities purchase agreement with certain purchasers, including certain of the Reporting Persons (the "Purchasers"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the "Private Placement") shares of the Issuer's Common Stock at a per share purchase price equal to $9.84.

F3 · price: Shares of the Issuer's Common Stock purchased in the Private Placement.

F6 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-23-002167 · form407422olma_09142023.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · Director · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,584,512

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · shares: The Issuer entered into a securities purchase agreement with certain purchasers, including certain of the Reporting Persons (the "Purchasers"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the "Private Placement") shares of the Issuer's Common Stock at a per share purchase price equal to $9.84.

F3 · shares: Shares of the Issuer's Common Stock purchased in the Private Placement.

F2 · price: The Issuer entered into a securities purchase agreement with certain purchasers, including certain of the Reporting Persons (the "Purchasers"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the "Private Placement") shares of the Issuer's Common Stock at a per share purchase price equal to $9.84.

F3 · price: Shares of the Issuer's Common Stock purchased in the Private Placement.

F5 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-23-002167 · form407422olma_09142023.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · Director · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,688,954

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · shares: The Issuer entered into a securities purchase agreement with certain purchasers, including certain of the Reporting Persons (the "Purchasers"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the "Private Placement") shares of the Issuer's Common Stock at a per share purchase price equal to $9.84.

F3 · shares: Shares of the Issuer's Common Stock purchased in the Private Placement.

F2 · price: The Issuer entered into a securities purchase agreement with certain purchasers, including certain of the Reporting Persons (the "Purchasers"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the "Private Placement") shares of the Issuer's Common Stock at a per share purchase price equal to $9.84.

F3 · price: Shares of the Issuer's Common Stock purchased in the Private Placement.

F4 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000935836-23-000733 · ownership.xml · nonDerivative · entry 1

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See note

Disclosed balance after: 1,668,130

F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-23-012922 · form4-09062023_010901.xml · nonDerivative · entry 2

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 998,714

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F3 · price: The weighted average sale price for the transaction reported was $11.62, and the range of prices were between $10.91 and $12.34. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-012922 · form4-09062023_010901.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,008,714

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $9.36, and the range of prices were between $9.22 and $9.60. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-012360 · form4-08172023_050801.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,023,714

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

SEC source: 0001415889-23-012898 · form4a-09052023_040904.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,023,714

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: On August 17, 2023, the reporting person filed a Form 4 that inadvertently excluded the weighted average sale price for the transaction. This amendment is being filed solely to report that the weighted average sale price for the transaction reported was $10.14, and the range of prices were between $9.765 and $10.65. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0000921895-23-001557 · form407422olma_06212023.xml · derivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · Director · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 21,520

Underlying: Common stock, $0.0001 par value · 21,520 shares

Expires 2033-06-15

F5 · security: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F6 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to Mr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Mr. Hrustanovic's continuous service through such vesting date.

F5 · ownership.direct: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F5 · ownership.nature: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

SEC source: 0001415889-23-010100 · form4-06212023_050601.xml · derivative · entry 1

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-23-010105 · form4-06212023_050618.xml · derivative · entry 1

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-23-010101 · form4-06212023_050603.xml · derivative · entry 1

BUTITTA CYNTHIA M · CIK 0001222082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-23-010104 · form4-06212023_050611.xml · derivative · entry 1

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-23-010106 · form4-06212023_050623.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-23-010102 · form4-06212023_050605.xml · derivative · entry 1

Hrustanovic Gorjan · CIK 0001821194 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

F2 · ownership.direct: The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001415889-23-010103 · form4-06212023_050607.xml · derivative · entry 1

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-23-009522 · form4-06092023_050601.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,038,714

F1 · price: The weighted average sale price for the transaction reported was $6.30, and the range of prices were between $6.30 and $6.32. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-009406 · form4-06072023_090601.xml · nonDerivative · entry 2

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,048,714

F3 · price: The weighted average sale price for the transaction reported was $6.295, and the range of prices were between $6.24 and $6.37. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.